CD8A and neoplasm: The outcome of single TIGIT blockade has exhibited limited or moderate antitumor effectiveness in experimental tumor models and in enhancing the in vitro functionality of human tumor-infiltrating CD8+ T cells (217, 218, 220, 225, 275).